4-alkoxy-2,6-dimethoxyphenethylamines (Ψ衍生物) 和相关的安非他胺的受体相互作用概况
Karolina E Kolaczynska1,2, Daniel Trachsel3, Marius C Hoener4
1Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Frontiers in pharmacology
|December 8, 2025
概括
这项研究探讨了新型迷幻化合物,4-替代的2,6-二甲基乙胺和安非他胺 (Ψ衍生物),揭示了它们与血清素受体的显著相互作用,特别是5-HT2A. 这些发现表明,有可能开发新的迷幻疗法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 神经科学是一个神经科学.
背景情况:
- 称为伪 (Ψ) 衍生物的4-替代的2,6-二甲基乙胺和安非他胺,代表了一类未经研究的迷幻化合物.
- 初步数据表明,这些 Ψ 衍生物在人类中具有强大的迷幻特性.
- 这项研究研究了这些新型化合物的受体和载体相互作用概况.
研究的目的:
- 描述各种4-alkyloxy-2,6-dimethoxyphenethylamines和安非他胺的单胺受体和载体相互作用.
- 为了比较这些 Ψ 衍生物的药理特征与相关的 3,4,5 和 2,4,5 替代类型.
- 评估关键的人类和动物受体和载体的结合 afinities 和激活功率.
主要方法:
- 在人类的5-HT1A,5-HT2A,5-HT2C,α1A,α2A,D2受体和人类单胺转运器上评估了结合亲和性.
- 还评估了与老鼠和小鼠的微氨酸相关受体1 (TAAR1) 的相互作用.
- 功能性测试确定了人类5-HT2A,5-HT2B和TAAR1.1中的激活强度.
主要成果:
- 测试的 Ψ 衍生物在人类的 5-HT2A 受体表现出中度至高的亲和力和活性,作为部分激动剂.
- 乙胺衍生物对5-HT1A和5-HT2C受体表现出中度的亲和力,而安非他胺衍生物对5-HT1A和5-HT2C受体表现出较弱的亲和力.
- 观察到与人类,老鼠和小鼠TAAR1以及与某些衍生品的α1A和α2A上腺受体有显著的相互作用.
结论:
- Ψ衍生物的主要药理标似乎是5-HT2A和5-HT2C受体.
- 与 2,4,5 和 3,4,5 替代的类似物相比, 2,6-二甲基替代模式可能会赋予明显的强度.
- 这些发现突显了 Ψ 衍生物作为具有特定受体相互作用配置文件的新型迷幻药物的潜力.
相关概念视频
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.5K
01:28Adrenergic Agonists: Mixed-Action Agents
1.4K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.4K
01:25Drug-Receptor Interaction: Agonist
3.7K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.7K
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.4K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.4K
01:28Drug-Receptor Interaction: Antagonist
4.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.6K